Cargando…
Management and investigation of neonatal encephalopathy: 2017 update
This review discusses an approach to determining the cause of neonatal encephalopathy, as well as current evidence on resuscitation and subsequent management of hypoxic-ischaemic encephalopathy (HIE). Encephalopathy in neonates can be due to varied aetiologies in addition to hypoxic-ischaemia. A com...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537522/ https://www.ncbi.nlm.nih.gov/pubmed/28389438 http://dx.doi.org/10.1136/archdischild-2015-309639 |
_version_ | 1783254197482815488 |
---|---|
author | Martinello, Kathryn Hart, Anthony R Yap, Sufin Mitra, Subhabrata Robertson, Nicola J |
author_facet | Martinello, Kathryn Hart, Anthony R Yap, Sufin Mitra, Subhabrata Robertson, Nicola J |
author_sort | Martinello, Kathryn |
collection | PubMed |
description | This review discusses an approach to determining the cause of neonatal encephalopathy, as well as current evidence on resuscitation and subsequent management of hypoxic-ischaemic encephalopathy (HIE). Encephalopathy in neonates can be due to varied aetiologies in addition to hypoxic-ischaemia. A combination of careful history, examination and the judicious use of investigations can help determine the cause. Over the last 7 years, infants with moderate to severe HIE have benefited from the introduction of routine therapeutic hypothermia; the number needed to treat for an additional beneficial outcome is 7 (95% CI 5 to 10). More recent research has focused on optimal resuscitation practices for babies with cardiorespiratory depression, such as delayed cord clamping after establishment of ventilation and resuscitation in air. Around a quarter of infants with asystole at 10 min after birth who are subsequently cooled have normal outcomes, suggesting that individualised decision making on stopping resuscitation is needed, based on access to intensive treatment unit and early cooling. The full benefit of cooling appears to have been exploited in our current treatment protocols of 72 hours at 33.5°C; deeper and longer cooling showed adverse outcome. The challenge over the next 5–10 years will be to assess which adjunct therapies are safe and optimise hypothermic brain protection in phase I and phase II trials. Optimal care may require tailoring treatments according to gender, genetic risk, injury severity and inflammatory status. |
format | Online Article Text |
id | pubmed-5537522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55375222017-08-03 Management and investigation of neonatal encephalopathy: 2017 update Martinello, Kathryn Hart, Anthony R Yap, Sufin Mitra, Subhabrata Robertson, Nicola J Arch Dis Child Fetal Neonatal Ed Review This review discusses an approach to determining the cause of neonatal encephalopathy, as well as current evidence on resuscitation and subsequent management of hypoxic-ischaemic encephalopathy (HIE). Encephalopathy in neonates can be due to varied aetiologies in addition to hypoxic-ischaemia. A combination of careful history, examination and the judicious use of investigations can help determine the cause. Over the last 7 years, infants with moderate to severe HIE have benefited from the introduction of routine therapeutic hypothermia; the number needed to treat for an additional beneficial outcome is 7 (95% CI 5 to 10). More recent research has focused on optimal resuscitation practices for babies with cardiorespiratory depression, such as delayed cord clamping after establishment of ventilation and resuscitation in air. Around a quarter of infants with asystole at 10 min after birth who are subsequently cooled have normal outcomes, suggesting that individualised decision making on stopping resuscitation is needed, based on access to intensive treatment unit and early cooling. The full benefit of cooling appears to have been exploited in our current treatment protocols of 72 hours at 33.5°C; deeper and longer cooling showed adverse outcome. The challenge over the next 5–10 years will be to assess which adjunct therapies are safe and optimise hypothermic brain protection in phase I and phase II trials. Optimal care may require tailoring treatments according to gender, genetic risk, injury severity and inflammatory status. BMJ Publishing Group 2017-07 2017-04-06 /pmc/articles/PMC5537522/ /pubmed/28389438 http://dx.doi.org/10.1136/archdischild-2015-309639 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Review Martinello, Kathryn Hart, Anthony R Yap, Sufin Mitra, Subhabrata Robertson, Nicola J Management and investigation of neonatal encephalopathy: 2017 update |
title | Management and investigation of neonatal encephalopathy: 2017 update |
title_full | Management and investigation of neonatal encephalopathy: 2017 update |
title_fullStr | Management and investigation of neonatal encephalopathy: 2017 update |
title_full_unstemmed | Management and investigation of neonatal encephalopathy: 2017 update |
title_short | Management and investigation of neonatal encephalopathy: 2017 update |
title_sort | management and investigation of neonatal encephalopathy: 2017 update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537522/ https://www.ncbi.nlm.nih.gov/pubmed/28389438 http://dx.doi.org/10.1136/archdischild-2015-309639 |
work_keys_str_mv | AT martinellokathryn managementandinvestigationofneonatalencephalopathy2017update AT hartanthonyr managementandinvestigationofneonatalencephalopathy2017update AT yapsufin managementandinvestigationofneonatalencephalopathy2017update AT mitrasubhabrata managementandinvestigationofneonatalencephalopathy2017update AT robertsonnicolaj managementandinvestigationofneonatalencephalopathy2017update |